Vaxart マネジメント

マネジメント基準チェック /24

現在、CEO に関する十分な情報がありません。

主要情報

Andy Floroiu

最高経営責任者

US$2.4m

報酬総額

CEO給与比率	19.4%
CEO在任期間	2.1yrs
CEOの所有権	n/a
経営陣の平均在職期間	2.1yrs
取締役会の平均在任期間	1.1yrs

経営陣の近況

Recent updates

CEO報酬分析

Vaxart の収益と比較して、Andy Floroiu の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Mar 31 2022	n/a	n/a	-US$80m
Dec 31 2021	US$2m	US$467k	-US$70m
Sep 30 2021	n/a	n/a	-US$64m
Jun 30 2021	n/a	n/a	-US$54m
Mar 31 2021	n/a	n/a	-US$47m
Dec 31 2020	US$3m	US$220k	-US$32m

報酬と市場: Andyの総報酬 ($USD 2.41M ) は、 German市場 ($USD 1.03M ) の同規模の企業の平均を上回っています。

報酬と収益: Andyの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Andy Floroiu (49 yo)

2.1yrs

在職期間

US$2,410,175

報酬

Mr. Cezar Andrei Floroiu, also known as Andy, M.B.A., serves as the Chief Executive Officer at Vaxart, Inc. since June 14, 2020 and served as Principal Financial Officer at Vaxart, Inc. since June 14, 2020...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Cezar Floroiu	CEO, President & Director	2.1yrs	US$2.41m	データなし
Sean Tucker	Senior VP & Chief Scientific Officer	12.4yrs	US$1.19m	データなし
James Cummings	Chief Medical Officer	less than a year	US$2.38m	データなし
Fuad Ahmad	Interim CFO and Principal Financial & Accounting Officer	less than a year	データなし	0.0040% € 21.2k
Edward Berg	Senior VP & General Counsel	less than a year	データなし	データなし
Shaily Garg	Senior Vice President of Clinical Development & Project Management	2.3yrs	データなし	データなし
Brant Biehn	Senior Vice President of Business Operations	4.3yrs	データなし	データなし
Rajesh Kapoor	Senior Vice President of Quality	1.5yrs	データなし	データなし
John Harland	Consultant	3.5yrs	US$418.05k	データなし

2.1yrs

平均在職期間

55yo

平均年齢

経験豊富な経営陣: NB11の経営陣は経験豊富であると考えられます ( 2.1年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Cezar Floroiu	CEO, President & Director	2.3yrs	US$2.41m	データなし
Robert Yedid	Lead Independent Director	2.8yrs	US$158.00k	0.0041% € 22.2k
Harry Greenberg	Member of Scientific & Clinical Advisory Board	less than a year	データなし	データなし
Karen Wilson	Independent Director	1.9yrs	US$158.00k	0% € 0
Todd Davis	Independent Chairman of the Board	2.8yrs	US$171.00k	0.094% € 502.7k
Michael Finney	Independent Director	15.5yrs	US$152.40k	0.52% € 2.8m
Stefan Gravenstein	Member of Scientific & Clinical Advisory Board	less than a year	データなし	データなし
David Wheadon	Independent Director	1.3yrs	US$485.94k	0% € 0
Robert Belshe	Member of Scientific & Clinical Advisory Board	less than a year	データなし	データなし
Marion Pepper	Member of Scientific & Clinical Advisory Board	less than a year	データなし	データなし
Ralph Baric	Member of Scientific & Clinical Advisory Board	less than a year	データなし	データなし
Gregory Gray	Member of Scientific & Clinical Advisory Board	less than a year	データなし	データなし

1.1yrs

平均在職期間

62yo

平均年齢

経験豊富なボード: NB11の取締役会は経験豊富ではない ( 1.1年の平均在任期間) ため、新しい取締役会が必要であると考えられます。

Vaxart マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Vaxart, Inc., Annual General Meeting, Jun 11, 2024

Vaxart, Inc. Announces Chief Executive Officer Changes

Vaxart, Inc. Announces CEO Changes

Vaxart, Inc. Names Phillip Lee as Chief Financial Officer

Vaxart, Inc. Appoints Ray Stapleton as Chief Technology Officer

Vaxart, Inc. Announces Board Changes

Recent updates

Vaxart, Inc. to Report Q3, 2024 Results on Nov 13, 2024

Vaxart, Inc. Announces Initiation of Sentinel Cohort for Phase 2B Study Evaluating its Covid-19 Oral Pill Vaccine Candidate

Vaxart Announces Publication in Vaccines of Preclinical Data Supporting the Potential of Its Mucosal Vaccine Technology Platform in Enabling Therapeutic Vaccination for Hpv-Related Cervical Dysplasia

Vaxart, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Vaxart Receives Written Notice from Nasdaq Due to Non-Compliance with the Minimum Bid Price Requirement Set Forth in Nasdaq Listing Rule 5550(a)(2) for Continued Listing on the Nasdaq Capital Market

Vaxart, Inc. Receives BARDA-Funded Project NextGen Award Valued Up to $453 Million to Conduct a Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate

Vaxart, Inc. to Report Q1, 2024 Results on May 13, 2024

Vaxart, Inc., Annual General Meeting, Jun 11, 2024

Vaxart, Inc. to Report Fiscal Year 2023 Results on Mar 14, 2024

Vaxart, Inc. Announces Chief Executive Officer Changes

Nasdaq Notifies Vaxart's Eligibility for an Additional 180-Day Compliance Period, or Until July 15, 2024, to Regain Compliance with the Bid Price Requirement

Vaxart, Inc. Announces CEO Changes

Vaxart, Inc. has filed a Follow-on Equity Offering in the amount of $10 million.

Vaxart, Inc. Announces Last Subject Dosed in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers

Vaxart Doses First Subject in Phase 1 Trial of its Norovirus Vaccine Candidate in Lactating Mothers

Vaxart, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Vaxart Announces Topline Data from the Phase 2 Challenge Study of Its Monovalent Norovirus Vaccine Candidate

Vaxart, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Vaxart Receives Written Notice from the Listing Qualifications Department of the Nasdaq Regarding Non-Compliance with the $1.00 Minimum Bid Price Requirement

Vaxart, Inc. Announces Positive Preliminary Topline Data from Dose-Ranging Phase 2 Study of its Bivalent Norovirus Vaccine Candidate

Vaxart, Inc.(NasdaqCM:VXRT) dropped from Russell 2000 Dynamic Index

Vaxart, Inc. Announces Last Subject Dosed in Phase 2 Trial of Its Bivalent Norovirus Candidate, and All Subjects Challenge Study of Monovalent Norovirus Candidate

Vaxart, Inc. Doses First Subject in the Phase 2 Clinical Trial of Its Bivalent Norovirus Candidate

Vaxart, Inc. Names Phillip Lee as Chief Financial Officer

Vaxart, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Vaxart, Inc. Announces Positive Top-line Phase II Clinical Study Data Demonstrating Safety and Immunogenicity of Its Wuhan S-Only COVID-19 Pill Vaccine Candidate

Vaxart, Inc. Appoints Ray Stapleton as Chief Technology Officer

Vaxart, Inc. Announces Board Changes

Vaxart, Inc. Appoints W. Mark Watson to Its Board of Directors

Vaxart, Inc. Publishes Clinical Data Suggesting its Oral COVID-19 Pill Vaccine Candidate Induces Long-Lasting Mucosal Immune Responses that are Highly Cross-Reactive

Vaxart, Inc. Presents New Preclinical Data Demonstrate Two of it's COVID-19 Vaccine Candidates Protect Against Omicron

Vaxart Reports Positive Preliminary Data from the Phase 1b Trial of its Oral Norovirus Vaccine Candidates in Elderly Adults

Vaxart Announces the Publication of Studies in the Peer-Reviewed Journal Science Translational Medicine That Suggest Mucosal Immunization Could Decrease SARS-CoV-2 Transmission

Vaxart, Inc. Announces Management Changes

Margaret Echerd Notifies as Senior Vice President and Principal Accounting Officer of Vaxart, Inc, Effective as of May 5, 2022

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Vaxart, Inc. Appoints Edward B. Berg as Senior Vice President and General Counsel

High number of new and inexperienced directors

Forecast to breakeven in 2024

High number of new and inexperienced directors

Forecast to breakeven in 2024

Vaxart to Test Cross-Reactivity of Its Covid-19 Oral Tablet Vaccine Against Omicron

No longer forecast to breakeven

High number of new and inexperienced directors

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /24